Enliven Therapeutics company information, Employees & Contact Information

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting PR Newswire

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data Yahoo Finance

Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire

ELVN Stock Price and Chart — NASDAQ:ELVN TradingView

Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares Nasdaq

Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option Stock Titan

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress PR Newswire

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates GlobeNewswire

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting PR Newswire

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress PR Newswire

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors Yahoo Finance

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update PR Newswire

How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41% Yahoo Finance

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update PR Newswire

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants PR Newswire

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update PR Newswire

Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know Nasdaq

Lyssikatos, chief scientific officer, sells Enliven Therapeutics shares Investing.com

Enliven Therapeutics: Awaiting Additional Trial Data (NASDAQ:ELVN) Seeking Alpha

Will Enliven Therapeutics Inc. stock continue dividend increases - 2025 Performance Recap & Daily Entry Point Trade Alerts Trung tâm Dự báo KTTV quốc gia

Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants Nasdaq

Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs Stock Titan

Enliven Therapeutics has cash runway into late 2026 BizWest

Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering Stock Titan

ENLIVEN THERAPEUTICS PROVIDES CORPORATE UPDATE ON FINANCING, EXPANSION OF BOARD AND LEADERSHIP TEAM PR Newswire

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million Yahoo Finance

Wilson Sonsini Advises Enliven Therapeutics on Merger with Imara Wilson Sonsini

Enliven Therapeutics and Imara Announce Merger Agreement GlobeNewswire

Enliven Therapeutics, troubled Imara set to merge with Roche-backed $165M fundraise Fierce Biotech

Enliven Therapeutics calls for advancements in CML treatments Traders Union

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 Defense World

Head-To-Head Analysis: Enliven Therapeutics (NASDAQ:ELVN) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) Defense World